The "RNA world" hypothesis proposes that the earliest life on Earth may have been based on RNA—a single-stranded molecule ...

Texas A&M AgriLife researchers uncovered a promising target for controlling gene expression and other cellular processes, ...

Researchers have identified unique RNA structures called G-quadruplexes (G4s) that promote harmful α-synuclein protein ...

HG202 is the first-ever clinical-stage CRISPR/Cas13 RNA-editing and the only clinical-stage RNA-targeting therapy for nAMD. “This open IND for HG202 by the US FDA – the first regulator to have cleared ...

A team of researchers at Kumamoto University has uncovered a mechanism in the formation of harmful protein aggregates that ...

Discover methods for accurate DNA and RNA quantification and learn how to analyze purity and concentration to enhance ...

The innate immune system is the body’s first line of defence against pathogens like bacteria or viruses. TRIM25 is a protein ...

RNA editing has picked up steam in recent years as a potentially safer alternative to gene editing to treat genetic diseases.

Australian scientists have successfully used an innovative gene therapy technique in the lab to combat a key cause of vision ...

Cancer, a disease with global impact, is intricately linked to dysregulated gene expression, which is influenced by both ...

Neuroblastoma (NB), the most prevalent extracranial solid tumor in children, poses a significant therapeutic challenge due to ...

HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company, announced that the U.S. FDA has cleared its investigational new drug (IND) application for HG202, the world's first ...